Patents by Inventor Ewelina Hegel
Ewelina Hegel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11796540Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: GrantFiled: July 26, 2019Date of Patent: October 24, 2023Assignee: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Patent number: 11391655Abstract: The present disclosure relates to an in vitro method for releasing analytes from a sample involving contacting the sample with (i) a chaotropic agent, (ii) an organic solvent, (iii) a detergent, and (iv) at least one agent providing bicarbonate ions. The present disclosure further relates to a release agent for releasing analytes from a sample having the aforesaid compounds. Moreover, the present disclosure relates to uses, kits, methods and devices related to the method and the release agent of the present disclosure.Type: GrantFiled: September 13, 2019Date of Patent: July 19, 2022Assignee: Roche Diagnostics Operations, Inc.Inventors: Eloisa Lopez-Calle, Ewelina Hegel, Thomas Fischer, Caroline Bylda, Hans-Peter Josel, Josef Roedl
-
Patent number: 10864200Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.Type: GrantFiled: September 6, 2019Date of Patent: December 15, 2020Assignee: Roche Diagnostics Operations, Inc.Inventors: Ewelina Hegel, Hans-Peter Josel, Eloisa Lopez-Calle, Josef Roedl, Noah Weiss, Benjamin Tiemann
-
Patent number: 10809258Abstract: A method for determination of the amount of a specific analyte in a sample which may show a prozone effect by photometric assays, wherein the specific analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific assay reagents. The optical signal is measured simultaneously for the specific analyte in the sample to be determined at the wavelength used for the determination of the analyte and at least at an additional specific wavelength used for the detection of the prozone effect over the complete reaction time. The reaction rate ratio R is calculated by using the signals obtained at the wavelength used for the detection of the prozone effect. By comparison of the calculated ratio value R with predetermined limit values it is judged if a prozone effect is present in the sample.Type: GrantFiled: February 12, 2016Date of Patent: October 20, 2020Assignee: Roche Diagnostics Operations, Inc.Inventors: Ewelina Hegel, Georg Kurz, Eloisa Lopez-Calle, Josef Roedl
-
Publication number: 20200003666Abstract: The present disclosure relates to an in vitro method for releasing analytes from a sample involving contacting the sample with (i) a chaotropic agent, (ii) an organic solvent, (iii) a detergent, and (iv) at least one agent providing bicarbonate ions. The present disclosure further relates to a release agent for releasing analytes from a sample having the aforesaid compounds. Moreover, the present disclosure relates to uses, kits, methods and devices related to the method and the release agent of the present disclosure.Type: ApplicationFiled: September 13, 2019Publication date: January 2, 2020Applicant: Roche Diagnostics Operations, Inc.Inventors: Eloisa Lopez-Calle, Ewelina Hegel, Thomas Fischer, Caroline Bylda, Hans-Peter Josel, Josef Roedl
-
Publication number: 20190388402Abstract: The present description relates to a liquid composition having at least one immune-modulatory macrolide compound and an essentially cell-free blood hemolysate. The present description further relates to a method for manufacturing a stabilized immune-modulatory macrolide calibration solution, by a) preparing a solution comprising an essentially cell-free blood hemolysate, b) admixing a predetermined amount of at least one immune-modulatory macrolide into said solution comprising an essentially cell-free blood hemolysate, and, thereby c) manufacturing a stabilized immune-modulatory macrolide calibration solution. Furthermore, the present description relates to kits, uses, devices, methods and to an immune-modulatory macrolide compound calibration solution related thereto.Type: ApplicationFiled: September 6, 2019Publication date: December 26, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Ewelina Hegel, Hans-Peter Josel, Eloisa Lopez-Calle, Josef Roedl, Noah Weiss, Benjamin Tiemann
-
Publication number: 20190346439Abstract: The disclosure includes a method for determining an analyte in a sample in an interaction assay, including contacting a sample with an interaction modulator, wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM), aminodextran, carboxymethyldextran, Poly-(2-acrylamido-2-methyl-1-propanesulfonic acid (PAMPS), triethylamine, triethanolamine, taurine, or dodecylsulfate. The disclosure includes a method for determining an analyte in an interaction assay, including contacting the sample with an interaction modulator, wherein the interaction modulator is an enhancer of the interaction assay at low analyte concentrations and is a retarder of the interaction assay at high analyte concentrations and wherein the interaction modulator is Poly-(4-styrenesulfonic acid-co-maleic acid) (PSSM) and/or Polyacrylic acid (PAA). The disclosure further relates to a kit having a detection agent specifically detecting an analyte and at least one interaction modulator.Type: ApplicationFiled: July 26, 2019Publication date: November 14, 2019Applicant: Roche Diagnostics Operations, Inc.Inventors: Georg Kurz, Eloisa Lopez-Calle, Ewelina Hegel, Josef Roedl, Eva Hoess, Joerg Kaufmann, Marisa Kirchenbauer
-
Publication number: 20160161480Abstract: A method for determination of the amount of a specific analyte in a sample which may show a prozone effect by photometric assays, wherein the specific analyte is quantified from the change in the optical signal of the reaction mixture after the interaction of the analyte with analyte specific assay reagents. The optical signal is measured simultaneously for the specific analyte in the sample to be determined at the wavelength used for the determination of the analyte and at least at an additional specific wavelength used for the detection of the prozone effect over the complete reaction time. The reaction rate ratio R is calculated by using the signals obtained at the wavelength used for the detection of the prozone effect. By comparison of the calculated ratio value R with predetermined limit values it is judged if a prozone effect is present in the sample.Type: ApplicationFiled: February 12, 2016Publication date: June 9, 2016Inventors: Ewelina Hegel, Georg Kurz, Eloisa Lopez-Calle, Josef Roedl